NASDAQ:ACAD ACADIA Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $40.45 -0.52 (-1.27 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$40.35Now: $40.45▼$41.4050-Day Range$36.42MA: $39.49▼$43.6352-Week Range$30.02Now: $40.45▼$58.72Volume807,203 shsAverage Volume1.05 million shsMarket Capitalization$6.38 billionP/E RatioN/ADividend YieldN/ABeta1.5 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.81, ACADIA Pharmaceuticals has a forecasted upside of 47.9% from its current price of $40.45.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.2 Community Rank Outperform VotesACADIA Pharmaceuticals has received 767 “outperform” votes. (Add your “outperform” vote.)Underperform VotesACADIA Pharmaceuticals has received 423 “underperform” votes. (Add your “underperform” vote.)Community SentimentACADIA Pharmaceuticals has received 64.45% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACAD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,532,812.00 in company stock.Percentage Held by InsidersOnly 27.70% of the stock of ACADIA Pharmaceuticals is held by insiders.Percentage Held by Institutions96.08% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($1.65) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -27.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -27.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 8.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD Previous Symbol CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone858-558-2871Debt Debt-to-Equity RatioN/A Current Ratio8.51 Quick Ratio8.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$339.08 million Price / Sales18.81 Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book8.91Profitability EPS (Most Recent Fiscal Year)($1.60) Net Income$-235,260,000.00 Net Margins-57.28% Return on Equity-33.49% Return on Assets-29.48%Miscellaneous Employees465 Outstanding Shares157,680,000Market Cap$6.38 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $40.45 -0.52 (-1.27 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ACAD News and Ratings via Email Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions How has ACADIA Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACAD stock has increased by 9.7% and is now trading at $40.45. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ACADIA Pharmaceuticals? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ACADIA Pharmaceuticals. When is ACADIA Pharmaceuticals' next earnings date? ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for ACADIA Pharmaceuticals. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.17. The biopharmaceutical company had revenue of $110.10 million for the quarter, compared to analysts' expectations of $105.65 million. ACADIA Pharmaceuticals had a negative return on equity of 33.49% and a negative net margin of 57.28%. View ACADIA Pharmaceuticals' earnings history. What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $437.26 million. What price target have analysts set for ACAD? 16 Wall Street analysts have issued 1 year price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $42.00 to $72.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $59.81 in the next twelve months. This suggests a possible upside of 47.9% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals. Who are some of ACADIA Pharmaceuticals' key competitors? Some companies that are related to ACADIA Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Beigene (BGNE), Genmab A/S (GMAB), Shiseido (SSDOY), UCB (UCBJF), Genmab A/S (GNMSF), Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Sarepta Therapeutics (SRPT). View all competitors. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Pfizer (PFE), Amarin (AMRN), Tesla (TSLA), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' key executives? ACADIA Pharmaceuticals' management team includes the following people: Mr. Stephen R. Davis, CEO & Director (Age 58)Dr. Srdjan R. Stankovic, Pres (Age 62)Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40) What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (13.19%), Vanguard Group Inc. (6.76%), Great Point Partners LLC (1.14%), First Trust Advisors LP (0.91%), Nuveen Asset Management LLC (0.78%) and Frontier Capital Management Co. LLC (0.76%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends for ACADIA Pharmaceuticals. Which institutional investors are selling ACADIA Pharmaceuticals stock? ACAD stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Vanguard Group Inc., Great Point Partners LLC, Peregrine Capital Management LLC, Prudential Financial Inc., Frontier Capital Management Co. LLC, State of Wisconsin Investment Board, and Charles Schwab Investment Management Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis. View insider buying and selling activity for ACADIA Pharmaceuticals. Which institutional investors are buying ACADIA Pharmaceuticals stock? ACAD stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, FMR LLC, Two Sigma Advisers LP, Cubist Systematic Strategies LLC, Columbus Circle Investors, Kornitzer Capital Management Inc. KS, Marshall Wace LLP, and Point72 Asset Management L.P.. View insider buying and selling activity for ACADIA Pharmaceuticals. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $40.45. How big of a company is ACADIA Pharmaceuticals? ACADIA Pharmaceuticals has a market capitalization of $6.38 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe. What is ACADIA Pharmaceuticals' official website? The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
